rejuvant life tabs

BioArctic receives European patent for Alzheimer’s antibodies

Latest articles

Paving the way to future organ factories

Extracellular matrix obtained by controlled decellularisation is used to reconstruct the liver with human-like characteristics, paving the way for transplantable livers. Researchers at the Human...

Charles Brenner: the journey from NR to Tru Niagen

Dr Charles Brenner, the developer of the intellectual property behind ChromaDex's Tru Niagen, on all things metabolism, NAD and NR clinical trials. Longevity.Technology: Following the...

Longevity investment firm announces acceleration programme

Call for future founders: longevity investment fund LongeVC announces in-house acceleration programme. LongeVC – a longevity investment group backed by an advisory board with solid...

The placenta: a limitless source of stem cells?

Part 1 of our exclusive interview with Celularity founder Dr Robert Hariri covers the discovery of placental pluripotent stem cells and the journey towards...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...
Supplement report

Editor's picks

Paving the way to future organ factories

Extracellular matrix obtained by controlled decellularisation is used to reconstruct the liver with human-like characteristics, paving the way for transplantable livers. Researchers at the Human...

Charles Brenner: the journey from NR to Tru Niagen

Dr Charles Brenner, the developer of the intellectual property behind ChromaDex's Tru Niagen, on all things metabolism, NAD and NR clinical trials. Longevity.Technology: Following the...

Longevity investment firm announces acceleration programme

Call for future founders: longevity investment fund LongeVC announces in-house acceleration programme. LongeVC – a longevity investment group backed by an advisory board with solid...
Rejuvant

European Patent Office grants Swedish biotech European patent for novel antibodies for Alzheimer’s therapy.

Stockholm-based BioArctic announced today that the European Patent Office (EPO) has issued a decision to grant European patent EP 2 448 968 B1 for novel antibodies that could be developed into a treatment for Alzheimer’s disease. The antibodies target a shorter (truncated) form of amyloid beta (pE3-Aβ) and are linked to the company’s project AD1503. The patent enters into force on 27 January 2021 and expires in 2030.

Longevity.Technology: BioArctic’s newly granted patent focuses on novel antibodies which target pE3-Ab, a specific truncated form of amyloid beta. Monomers of pE3-Ab are highly prone to aggregate, leading to the formation of harmful soluble Ab aggregates which cause debilitating cognitive and other symptoms in Alzheimer’s disease. This patent is good news, both for the brain diseases field in general and for Alzheimer’s disease research specifically.

BioArctic was founded in 2003 based on innovative research from Uppsala University, Sweden. Focused on disease-modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, BioArctic has previously forged global partnerships with Eisai, on its Alzheimer’s project and with AbbVie on its Parkinson’s projects. Its project portfolio is a combination of fully-funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market and out-licensing potential.

 


 

“More than 30 million people around the world live with Alzheimer’s disease today and there is a large medical need. We continue to work tirelessly to develop and give these patients access to the treatments they deserve.”

 


 

Alzheimer’s disease is fatal. As the disease progresses, it becomes not only incredibly debilitating, with serious cognitive and motor symptoms, but an enormous burden on families and healthcare systems. The most common form of dementia, Alzheimer’s accounts for 60-80% of all diagnosed dementias [1]; more than 30 million people worldwide are thought to suffer from Alzheimer’s disease today with that number expected to triple in 30 years. Understandably, the researchers are under pressure to develop therapies that can ameliorate, cure and even prevent Alzheimer’s disease, an outcome that would dovetail with extending lifespan and healthspan.

Elevant

By focusing on additional forms of amyloid beta species in the disease cascade, BioArctic is broadening the company’s scope to affect the disease pathology in addition to lecanemab (BAN2401), the company’s primary Alzheimer’s disease drug candidate currently in phase 3; this widens the field for future treatment possibilities.

“We are pleased that our patent has been granted for these novel antibodies,” said Gunilla Osswald, CEO, BioArctic. “More than 30 million people around the world live with Alzheimer’s disease today and there is a large medical need. We continue to work tirelessly to develop and give these patients access to the treatments they deserve.”

Elevant

[1] https://www.alz.org/media/homeoffice/facts%20and%20figures/facts-and-figures.pdf

Comment on this article

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.
Rejuvant

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...
Supplement report

Related articles

Paving the way to future organ factories

Extracellular matrix obtained by controlled decellularisation is used to reconstruct the liver with human-like characteristics, paving the way for transplantable livers. Researchers at the Human...

The placenta: a limitless source of stem cells?

Part 1 of our exclusive interview with Celularity founder Dr Robert Hariri covers the discovery of placental pluripotent stem cells and the journey towards...

Insulin – predictor of longevity

Body weight stands for far more than simple aesthetics – it is key for longevity. From a single cell to a fully functioning human adult,...

Juvenescence debuts ketosis longevity supplement drink

Biotech Juvenescence's new product Metabolic Switch is a drink that supports healthy aging and a healthy metabolism by generating a state of ketosis. It's been...

Targeting neurodegeneration with $82m Series A

Alchemab raises £60 million to advance novel platform for identifying disease-modifying antibody therapeutics for neurodegeneration, cancer and more. UK-based biotech Alchemab Therapeutics has secured a...
Supps report ad middle